ClinicalTrials.gg
RecruitingNCT06685237CPH-HFpEFUpdated Mar 5, 2025

Copenhagen Heart Failure With Preserved Ejection Fraction

An observational study in Heart Failure With Preserved Ejection Fraction (HFPEF), sponsored by Tor Biering-Sørensen. Recruiting at 1 site in Denmark. Open to participants aged 50 Years to 89 Years. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by Tor Biering-Sørensen · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
50 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 242 studies in Heart Failure with a site in Denmark — 52 open to participants now, 60 under way, 9 of them phase 3. Heart Failure · Denmark.

Planned enrollment
6th of 54
5,000 · median 213
Started
2025
with 9 others
Observational
54 of 242
19 open now
Primary completion
2025-11
later than 11 of 59 live
Registered
223rd of 242
by date

Among the 242 studies in Heart Failure with a site in Denmark, this one is the 6th largest by planned enrollment of the 54 observational ones that give a count, is one of 10 that started in 2025, is one of 54 observational ones, reaches primary completion later than 11 of the 59 other live ones, and was the 223rd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

52 of the 242 studies in Heart Failure with a site in Denmark are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 50 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 242 studies in Heart Failure with a site in Denmark, or all of them as a file.
02

Study summary

Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant form of heart failure (HF) worldwide, in tandem with ageing of the general population and the increasing prevalence of obesity, diabetes mellitus and hypertension. In 2020, > 70% of patients with heart failure had preserved ejection fraction. The incidence and prevalence of HFpEF has been growing by 10% every 10 years relative to HF with reduced ejection fraction (HFrEF). In 2017, the prevalence of HFpEF varied from 1% to 14% based on available data from Europe and USA. HFpEF is associated with high morbidity and mortality, and patients with HFpEF have similarly high hospitalization rates as patients with HFrEF. Hence, HFpEF poses a substantial global health challenge. Despite its prevalence, HFpEF remains undiagnosed and underrecognized, necessitating a comprehensive approach to both identification and management.

Ensuring successful treatment necessitates early identification of HFpEF. Consequently, a targeted screening strategy has been devised for the identification of HFpEF patients. Given the higher prevalence of heart failure (HF) in the elderly population, testing the screening strategy is imperative to customize it to the specific needs of vulnerable patients who may be more inclined to decline participation in the screening program.

Read the detailed description

The study is a prospective, observational cohort study. Using risk factors for HFpEF, the Danish National Health Registries will be used to identify up to 5000 citizens with at least one risk factor for HFpEF relying on International Classification of Diseases, 10th revision (ICD-10), medication, and biochemistry. The investigators will only recruit patients from the Capital Region of Denmark. Participants will be recruited by sending recruitment letters to a secure electronic mailbox (eBoks) linked to the patients' social security numbers.

The purpose of this study is to evaluate the identification and screening procedures for HFpEF outlined in this protocol. Additionally, the investigators aim to gauge the willingness of identified Danish adults with risk factors for HFpEF to participate in the study and to identify and address any barriers to their involvement. Overall, the investigators expect the results of this study can be used to guide future initiatives aimed at improving the identification and enrollment of patients with HFpEF, particularly among vulnerable populations.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction (HFPEF)

Browse trials for

Keywords

  • Heart failure with preserved ejection fraction
  • HFpEF
  • Registry
  • Screening
  • Echocardiography
  • Questionnaire
  • NT-proBNP
04

Who can participate

Ages eligible
50 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

5000 citizens aged 50 years or above in the Capital Region of Denmark with at least two risk factors for HFpEF (for age ≥ 60 years, only one).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Residence in the Capital Region of Denmark
  2. Age ≥ 50 years
  3. At least two risk factors for HFpEF defined as any of the following (for age ≥ 60 years, only one):

    • Hypertension
    • Diabetes mellitus
    • Chronic kidney disease
    • Atrial fibrillation
    • > 25 kg/m2
    • Previous heart valve surgery
    • Ischemic heart disease
    • Obstructive sleep apnea
    • Furosemide 40 mg

Exclusion criteria

Exclusion Criteria:

  1. Age ≥ 90 years
  2. Prevalent HF
  3. Dementia
  4. Nursing home
  5. Amyloidosis
  6. Hemodialysis
  7. Cancer diagnosed within the past 5 years (skin cancer not included)
  8. Prior solid organ transplantation
  9. Lung disease defined as any of the following:

    • World Health Organization Group 1 pulmonary hypertension
    • Chronic pulmonary embolism
    • Lung fibrosis
    • (COPD)
    • Home oxygen
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. The primary objective of this study is to pilot the identification and screening procedures outlined in this protocol.

    The primary objective of this study is to pilot the identification and screening procedures outlined in this protocol. This includes assessing the identification rate (%) and estimating the prevalence of heart failure with preserved ejection fraction (HFpEF) both overall and within different subgroups (%).

    Time frame: From the invitation date until the end of the study (approximately 12 months).

Secondary outcomes

  1. Secondarily, we aim to assess the willingness of identified Danish adults with risk factors for HFpEF to participate in the study, as well as to identify and address any barriers to their involvement.

    * To assess response, acceptance, and attendance rates among participants, reported as percentages. * To investigate barriers to participation, categorizing and presenting them as percentages. * To analyze patterns among non-responders, using educational attainment, household income, and geographic distances to the study site as indicators of socioeconomic and sociodemographic status. All parameters will be clustered and reported as percentages. Through these objectives, we aim to gain a comprehensive understanding of participant engagement and identify any factors that may hinder participation in the screening process.

    Time frame: From the end of the study until all analyses are completed (estimated to be from November 2025 to March 2026

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Most data will be collected from Danish administrative health registries, which are subject to Danish legislation and can only be made available to a third party under certain conditions. Please contact the sponsor-investigator in case of any inquiries.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Nov 2025, 9 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 9 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2024
First posted
Nov 12, 2024
StartActual
Feb 28, 2025
Primary completionEst.
Nov 28, 2025
CompletionEst.
Mar 28, 2026
Last update
Mar 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06685237
Lead sponsor
Tor Biering-Sørensen
Responsible party
Tor Biering-Sørensen (Professor, Herlev and Gentofte Hospital) — Sponsor-investigator
First posted
Nov 12, 2024
Start date
Feb 28, 2025
Primary completion
Nov 28, 2025 (estimated)
Completion
Mar 28, 2026 (estimated)
Last update
Mar 5, 2025

Study contacts

Camilla I Ottosen, MD
Contact
camilla.ikast.ottosen@regionh.dk
+4538674143
Tor Biering-Sørensen, MD, MPH, MSc, PhD
Contact
tor.biering@gmail.com
+4528933590

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion